Filtered By:
Vaccination: Ebola Vaccine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 123 results found since Jan 2013.

Expanding Research Capacity in Sub-Saharan Africa Through Informatics, Bioinformatics, and Data Science Training Programs in Mali
Conclusion Bioinformatics and data science training programs in developing countries necessitate incremental and collaborative strategies for their feasible and sustainable development. The progress described here covered decades of collaborative efforts centered on training and research on computationally intensive topics. These efforts laid the groundwork and platforms conducive for hosting a bioinformatics and data science training program in Mali. Training programs are perhaps best facilitated through Africa’s university systems as they are perhaps best positioned to maintain core resources during lapses in sho...
Source: Frontiers in Genetics - April 11, 2019 Category: Genetics & Stem Cells Source Type: research

Editorial: Shaping of Human Immune System and Metabolic Processes by Viruses and Microorganisms
Conclusions In conclusion, articles in this Research Topic made a very significant contribution to our understanding of the role played by environmental factors, dysbiotic conditions, and infections in triggering diseases. Since this is a rapidly expanding area of research, many other factors contributing to the onset of these diseases are not covered here. We are confident, however, that further studies will expand the list as well as bring a better understanding of mechanisms involved in the onset of autoimmune and autoinflammatory diseases. Author Contributions All authors listed have made a substantial, direct and i...
Source: Frontiers in Microbiology - April 16, 2019 Category: Microbiology Source Type: research

NIH to Launch human safety study of Ebola vaccine candidate
(NIH/National Institute of Allergy and Infectious Diseases) Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline and will evaluate the experimental vaccine's safety and ability to generate an immune system response in healthy adults. Testing will take place at the NIH Clinical Center in Bethesda, Maryland.
Source: EurekAlert! - Infectious and Emerging Diseases - August 28, 2014 Category: Infectious Diseases Source Type: news

Genes may play a role in Ebola survival chances
Conclusion This research across mouse strains demonstrates that mice with different genetic profiles show variable disease response after infection with the Ebola virus. Responses ranged from complete resistance to infection with full recovery, to fatal disease, with or without changes consistent with Ebola haemorrhagic fever. When comparing the mice that were resistant with those that developed fatal Ebola haemorrhagic syndrome, they found differences in the activity of certain genes, which was associated with different immune and inflammatory response. However, these results in mice should not be extrapolated too far ...
Source: NHS News Feed - October 31, 2014 Category: Consumer Health News Tags: Genetics/stem cells Medical practice Source Type: news

NIAID/GSK experimental Ebola vaccine appears safe, prompts immune response
(NIH/National Institute of Allergy and Infectious Diseases) An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.
Source: EurekAlert! - Infectious and Emerging Diseases - November 26, 2014 Category: Infectious Diseases Source Type: news

Ebola vaccine trial opens in Liberia
(NIH/National Institute of Allergy and Infectious Diseases) A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-US clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the NIH.
Source: EurekAlert! - Infectious and Emerging Diseases - February 2, 2015 Category: Infectious Diseases Source Type: news

Investigational monoclonal antibody to treat Ebola is safe in adults
(NIH/National Institute of Allergy and Infectious Diseases) The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the NIH Clinical Center in Bethesda, Md. The National Institute of Allergy and Infectious Diseases' Vaccine Research Center developed the investigational treatment and conducted and sponsored the trial.
Source: EurekAlert! - Infectious and Emerging Diseases - January 24, 2019 Category: Infectious Diseases Source Type: news

Antigen-Specific Single B Cell Sorting and Monoclonal Antibody Cloning in Guinea Pigs
This study was supported by NIH/NIAID grants R01AI102766 (YL), P01AI104722 (RW and YL), UM1 AI100663 (RW), and Bill and Melinda Gates Foundation grant OPP1084519 (RW). JS is a trainee of NIH training grant T32AI125186A to Anne Simon at University of Maryland, College Park. This study was also partially funded by the International AIDS Vaccine Initiative (IAVI) (RW) with the generous support of United States Agency for International Development (USAID), and Ministry of Foreign Affairs of the Netherlands. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or ...
Source: Frontiers in Microbiology - April 22, 2019 Category: Microbiology Source Type: research

Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5"},"comscore":{"clientId"...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news

NIH scientists identify protective role for antibodies in Ebola vaccine study
(NIH/National Institute of Allergy and Infectious Diseases) Researchers at NIH and Oregon Health & Science University have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection. Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates, meaning that infection may lead to shock, bleeding and multi-organ failure. According to the World Health Organization, Ebola hemorrhagic fever has a fatality rate of up to 90 percent. There is no licensed treatment or vaccine for Ebola virus infection.
Source: EurekAlert! - Medicine and Health - January 14, 2013 Category: Global & Universal Source Type: news

Rapid and durable protection against ebola virus with new vaccine regimens
(NIH/National Institute of Allergy and Infectious Diseases) One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector, called chimp adenovirus type 3 or ChAd3, protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, report National Institutes of Health scientists and their collaborators.
Source: EurekAlert! - Infectious and Emerging Diseases - September 8, 2014 Category: Infectious Diseases Source Type: news

NIH grants license agreement for candidate Ebola vaccines
(NIH/National Institute of Allergy and Infectious Diseases) NIAID today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. The vaccines were created by scientists at NIAID and Thomas Jefferson University in Philadelphia and are being further developed through a partnership with the German pharmaceutical company IDT Biologika. The candidate vaccines now have been licensed to Exxell BIO of Saint Paul, Minnesota, which aims to advance the products through clinical testing and commercialization.
Source: EurekAlert! - Medicine and Health - October 15, 2014 Category: Global & Universal Source Type: news

NIH begins early human clinical trial of VSV Ebola vaccine
(NIH/National Institute of Allergy and Infectious Diseases) Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center. Researchers at NIAID are conducting the early phase trial to evaluate the vaccine, called VSV-ZEBOV, for safety and its ability to generate an immune system response in healthy adults who are given two intramuscular doses, called a prime-boost strategy. The Walter Reed Army Institute of Research is simultaneously testing the vaccine candidate as a single dose at its Clinical Trials Center.
Source: EurekAlert! - Infectious and Emerging Diseases - October 22, 2014 Category: Infectious Diseases Source Type: news

Ebola Vaccine Appears Safe In First-Stage Testing
WASHINGTON (AP) — An experimental Ebola vaccine appears safe and triggered signs of immune protection in the first 20 volunteers to test it, U.S. researchers reported Wednesday. The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health. Half of the test group received a higher-dose shot, and those people produced more antibodies, said the study published in the New England Journal of Medicine. Some people also developed a different set of virus-fighting immune cells, named T cells, the stu...
Source: Healthy Living - The Huffington Post - November 27, 2014 Category: Consumer Health News Source Type: news

Ebola in the United States
The ongoing epidemic of Ebola virus in West Africa and attendant cases described in other parts of the world has focused attention on this heretofore rare disease. In this brief opinion article, we provide a short primer on the epidemiology, pathogenesis, clinical manifestations, US-based hospital preparedness, vaccine and therapy development, and control of Ebola virus disease for noninfectious disease physicians.
Source: Journal of Allergy and Clinical Immunology - December 20, 2014 Category: Allergy & Immunology Authors: Robert Lindblad, Ashraf El Fiky, Thad Zajdowicz Tags: Rostrum Source Type: research